- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04265807
Remote Ischemic Conditioning to Enhance Resuscitation (RICE) Pilot
February 7, 2020 updated by: Graham Nichol, University of Washington
Following resuscitation from out-of-hospital cardiac arrest (OHCA), reperfusion injury can cause cell damage in the heart and brain.
Remote ischemic conditioning (RIC) consists of intermittent application of a device such as a blood pressure cuff to a limb to induce non-lethal ischemia.
Studies in animals with cardiac arrest as well as in humans with acute myocardial infarction suggest that RIC before or after restoration of blood flow may reduce injury to the heart and improve outcomes but this has not been proven in humans who have had OHCA.
The RICE pilot study is a single-center study to assess the feasibility of application of RIC in the emergency department setting for patients transported to the hospital after resuscitation from OHCA.
Study Overview
Status
Unknown
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Anticipated)
30
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Graham Nichol, MD, MPH
- Phone Number: 206-521-1722
- Email: ricstudy@uw.edu
Study Contact Backup
- Name: Emily Bartlett, MD
- Phone Number: 206 521 1722
- Email: ricstudy@uw.edu
Study Locations
-
-
Washington
-
Seattle, Washington, United States, 98104
- Recruiting
- Graham Nichol
-
Contact:
- Graham Nichol, MD MPH
- Phone Number: 206-521-1722
- Email: ricstudy@uw.edu
-
Contact:
- Emily S Bartlett, MD MS
- Email: ricstudy@uw.edu
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Included will be those with:
- Age 18 years or more;
- Defibrillation by laypersons or defibrillation and/or chest compressions by EMS providers dispatched to the scene;
- Non-traumatic etiology of arrest, defined as without concomitant blunt, penetrating, or burn-related injury, or uncontrolled bleeding or exsanguination;
- Spontaneous circulation upon emergency department arrival;
- No response to verbal commands; and
- Ongoing or planned induced hypothermia.
Excluded will be those with:
- STEMI indicated on first 12-lead ECG obtained after restoration of circulation, defined as ST-elevation of ≥2 mm in two or more contiguous ECG leads;
- Written do not attempt resuscitation (DNAR) reported to providers before randomization;
- Drowning or hypothermia as cause of arrest;
- Known prisoner or pregnant; or
- Dialysis fistula in either upper extremity; or
- Pre-existing amputation of upper extremity.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: DOUBLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
ACTIVE_COMPARATOR: Intervention Group
A standard non-invasive blood pressure cuff (e.g., American Diagnostics Corporation, Hauppauge, NY but any one can be used off the shelf) and disposable plastic clamp (e.g.,Medline Industries Incorporated, Mundelein, IL) can be used to apply RIC in patients resuscitated from OHCA via three cycles of 5-mins.
inflation to 200 mmHg followed by 5-mins.
deflation of a blood pressure cuff on an upper extremity.
The cuff occludes the artery; the clamp maintains pressure in the air bladder of the cuff during the inflation periods.
|
A standard non-invasive blood pressure cuff (e.g., American Diagnostics Corporation, Hauppauge, NY but any one can be used off the shelf) and disposable plastic clamp (e.g.,Medline Industries Incorporated, Mundelein, IL) can be used to apply RIC in patients resuscitated from OHCA via three cycles of 5-mins.
inflation to 200 mmHg followed by 5-mins.
deflation of a blood pressure cuff on a upper extremity.
The cuff occludes the artery; the clamp maintains pressure in the air bladder of the cuff during the inflation periods.
|
SHAM_COMPARATOR: Control Group
The control group will have a sham package opened at the bedside as soon as feasible after ED arrival.
This will be identical in size, weight and appearance as that in the intervention group, but will contain a sham device.
Upon identification that the patient has been randomized to the control group, the care team will proceed with all other resuscitative measures as in the the intervention group.
|
The control group will have a sham package opened at the bedside as soon as feasible after ED arrival.
This will be identical in size, weight and appearance as that in the intervention group, but will contain a sham device.
Upon identification that the patient has been randomized to the control group, the care team will proceed with all other resuscitative measures as in the the intervention group.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Attrition
Time Frame: 30 minutes from initiation of study intervention
|
Attrition assessed as the proportion of randomized subjects who do not remain on allocated therapy for the intended study duration among subjects randomly allocated.
On therapy for the intended study duration consists of completing three cycles of inflation-deflation.
|
30 minutes from initiation of study intervention
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Treatment Success
Time Frame: 30 minutes from initiation of study intervention
|
Treatment Success assessed as the proportion of intervention group patients who remain alive and on their allocated therapy for the intended study duration.
|
30 minutes from initiation of study intervention
|
Cardiac Function
Time Frame: Within 48 hours of index arrest
|
Cardiac Function assessed as left ventricular ejection fraction (LVEF) using echocardiograms ordered for clinical indications.
|
Within 48 hours of index arrest
|
Cardiogenic Shock
Time Frame: Within 48 hours of index arrest
|
Cardiogenic Shock assessed as systolic BP < 80 mmHg during any 6 h period within 48 h of the index arrest not due to a correctable cause, and treated with pressors or inotropes or placement of a mechanical cardiac assist device (e.g.
intra-aortic balloon pump).
Cardiogenic shock correlates with survival after resuscitation from cardiac arrest.
|
Within 48 hours of index arrest
|
STEMI
Time Frame: Within 48 hours of index arrest
|
STEMI assessed as the presence of electrocardiographic (ECG) and biomarker criteria for acute myocardial infarction within 48 h of the index arrest.
Note that ST-elevation on the first 12-lead ECG after resuscitation is a poor predictor of acute infarction in this population.
These patients often develop infarctions during the subsequent 48 h.
|
Within 48 hours of index arrest
|
Myocardial Injury
Time Frame: Within 24 hours of index arrest
|
Myocardial Injury assessed as peak serum troponin in ng/mL at any time point within 24 h of index arrest.
|
Within 24 hours of index arrest
|
Renal Dysfunction
Time Frame: Within 24 hours of index arrest
|
Renal Dysfunction assessed using Risk, Injury, Failure, Loss, End Stage criteria.
|
Within 24 hours of index arrest
|
Hospital Free Survival
Time Frame: Within 30 days of index arrest
|
Hospital Free Survival (HFS) assessed as number of days alive and permanently out of hospital up to 30 days post arrest
|
Within 30 days of index arrest
|
Withdrawal of Care
Time Frame: Discharge or 30 days after index arrest
|
assessed as the reduction of support (i.e.
reducing pressors, lab draws or medications) or withdrawal of support (i.e.
extubation, stopping drips/meds, changing to comfort care only) during hospitalization.
|
Discharge or 30 days after index arrest
|
Favourable Neurologic Status at Discharge
Time Frame: Discharge or 30 days after index arrest
|
Favourable Neurologic Status at Discharge assessed using modified Rankin Score (MRS) < 3 at hospital discharge or 30 days after index arrest.
|
Discharge or 30 days after index arrest
|
Survival to Discharge
Time Frame: Dicharge or 30 days after index arrest
|
Survival to Discharge assessed as alive when discharged from hospital to home, nursing facility or rehabilitation.
Patients transferred to another acute care facility (e.g. to undergo implantable defibrillator placement) will be considered still hospitalized.
|
Dicharge or 30 days after index arrest
|
Clinical Instability at Discharge
Time Frame: Discharge or 30 days after index arrest
|
Clinical Instability at Discharge assessed using the Kosecoff Index measured at discharge based on the presence of nine symptoms and signs associated with increased risk of rehospitalization.
Instability will be the presence of any of these.
|
Discharge or 30 days after index arrest
|
Survival to 30 days after arrest
Time Frame: 30 days after index arrest
|
Survival to 30 Days After Cardiac Arrest assessed as alive 30 days after the index cardiac arrest as confirmed by a brief telephone interview.
|
30 days after index arrest
|
Accrual
Time Frame: Through study completion, an average of 6 mos.
|
Accrual is the proportion of eligible subjects who have the study device applied
|
Through study completion, an average of 6 mos.
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Device Failure
Time Frame: 30 minutes from initiation of study intervention
|
device failure will be defined as discontinuation of use of the device prior to the end of allocated treatment interval because of mechanical failure as opposed to provider preference.
|
30 minutes from initiation of study intervention
|
Expected Adverse Event Related to Device- Pain
Time Frame: Within 24 hours of Enrollment
|
Pain assessed using the Richmond Agitation-Sedation Scale at 30 and 60 minutes after randomization in control and intervention group patients.
No gold standard exists for pain assessment in sedated and ventilated patients.
|
Within 24 hours of Enrollment
|
Expected Adverse Event Related to Device- Thrombophlebitis
Time Frame: Within 1 week of Enrollment
|
Thrombophlebitis assessed as symptomatic non central nervous system venous or arterial thrombus documented radiographically or ultrasonographically in the upper extremity to which the study intervention was applied.
|
Within 1 week of Enrollment
|
Expected Adverse Event Related to Device- Sepsis
Time Frame: Within 1 week of Enrollment
|
Sepsis assessed within one week of index arrest as either i) the presence of microbiologically proven, clinically proven, or suspected infection; or ii) presence of Systemic Inflammatory Response Syndrome (SIRS); and iii) development of at least one organ dysfunction within the preceding 24 hours.
|
Within 1 week of Enrollment
|
Expected Adverse Event Related to Cardiac Arrest
Time Frame: Discharge or 30 days after index arrest
|
Related to Cardiac Arrest The following are commonly observed in patients who experience cardiac arrest, and may or may not be attributable to specific resuscitation therapies.
These will be monitored and reported but not classified as serious adverse events.
Clinical diagnoses of pneumonia, cerebral bleeding, stroke, seizures, bleeding requiring transfusion or surgical intervention, rearrest, pulmonary edema, serious rib fractures, sternal fractures, internal thoracic or abdominal injuries as noted in the hospital discharge summary.
|
Discharge or 30 days after index arrest
|
Unexpected Adverse Event
Time Frame: Discharge or 30 days after index arrest
|
These will be defined as any serious unexpected adverse effect on health or safety or any unexpected life-threatening problem caused by, or associated with, a device, if that effect or problem was not previously identified in nature, severity, or degree of incidence in the investigation plan or application, or any other unexpected serious problem associated with a device that relates to the rights, safety or welfare of subjects.
Death or neurological impairment will not be considered an adverse event in this study, as it is an expected part of the natural history of the illness for a large proportion of the population.
|
Discharge or 30 days after index arrest
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Emilby S Bartlett, MD MS, University of Washington
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ANTICIPATED)
February 7, 2020
Primary Completion (ANTICIPATED)
August 7, 2020
Study Completion (ANTICIPATED)
January 7, 2021
Study Registration Dates
First Submitted
January 15, 2020
First Submitted That Met QC Criteria
February 7, 2020
First Posted (ACTUAL)
February 12, 2020
Study Record Updates
Last Update Posted (ACTUAL)
February 12, 2020
Last Update Submitted That Met QC Criteria
February 7, 2020
Last Verified
February 1, 2020
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- STUDY00005176
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
YES
IPD Plan Description
Available upon request, subject to mutual agreement
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- CSR
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cardiac Arrest
-
Italian Resuscitation CouncilUnknownOut-Of-Hospital Cardiac Arrest | In-hospital Cardiac ArrestItaly
-
Australian and New Zealand Intensive Care Research...Ambulance VictoriaNot yet recruitingOut of Hospital Cardiac Arrest
-
University Medical Centre MariborRecruiting
-
IRCCS Policlinico S. MatteoOslo University Hospital; University of the Basque Country (UPV/EHU); The Hospital...CompletedOut-Of-Hospital Cardiac ArrestItaly, Norway, Spain
-
Lithuanian University of Health SciencesEgle Vaitkaitiene; Dinas Vaitkaitis; Asta Krikscionaitiene; Ilona Kajokaite; Nerijus...CompletedOut-Of-Hospital Cardiac ArrestLithuania
-
Ceric SàrlAbbottTerminatedOut of Hospital Cardiac ArrestBelgium, France, Serbia
-
Prehospital Center, Region ZealandCompletedOut-Of-Hospital Cardiac Arrest
-
Karolinska InstitutetSwedish Heart Lung FoundationCompletedCardiac Arrest | Out of Hospital Cardiac ArrestSweden
-
Karolinska InstitutetVastra Gotaland Region; SOS Alarm Sverige AB; Everdrone AB; Aviation capacity resources... and other collaboratorsCompleted
-
Brno University HospitalTerminatedOut-Of-Hospital Cardiac ArrestCzechia
Clinical Trials on Active Remote Ischemic Conditioning
-
Bronx VA Medical CenterCompletedAmyotrophic Lateral Sclerosis | Spinal Cord InjuriesUnited States
-
University of AarhusNovo Nordisk A/S; Aarhus University Hospital; University Medical Center Groningen and other collaboratorsUnknownKidney Transplantation | Acute Kidney Injury | Glomerular Filtration Rate | Delayed Graft FunctionNetherlands, Denmark, Sweden
-
Yi YangRecruiting
-
University of ArizonaRecruitingBrain Injuries | Brain Injuries, Traumatic | Traumatic Brain Injury | Brain TraumaUnited States
-
Grethe AndersenCompletedCerebrovascular Disorders | Central Nervous System Diseases | Ischemic Stroke | Stroke, AcuteDenmark
-
Rutgers, The State University of New JerseyUnknownLiver Diseases | Urologic Diseases | Pancreatic Diseases | Complication of Surgical Procedure | Laparotomy | Laparoscopy | Gastrointestinal Disease | Retroperitoneal Disease | Pelvis DiseaseUnited States
-
Capital Medical UniversityUnknown
-
Capital Medical UniversityUnknownAneurysm, Ruptured | Coiling TherapyChina
-
Capital Medical UniversityRecruiting
-
Yi YangRecruitingAcute Ischemic StrokeChina